Can biochemical markers predict bone loss at the hip and spine?: A 4-year prospective study of 141 early postmenopausal women Original Article Received: 26 June 1995 Accepted: 13 May 1996 DOI:
Cite this article as: Keen, R.W., Nguyen, T., Sobnack, R. et al. Osteoporosis Int (1996) 6: 399. doi:10.1007/BF01623014 Abstract
A number of recent studies have suggested that non-invasive measures of bone turnover are associated with bone loss at the forearm in postmenopausal women. Whether bone turnover markers are predictive of bone loss from the clinically important sites of lumbar spine and femoral neck remain unclear, and was the aim of this 4-year prospective study. One hundred and forty-one normal, postmenopausal women (mean age 52.0±3.3 years, mean menopause duration 20.4±5.7 months) were recruited for the study in 1988. Fasting early morning samples of blood and urine were collected at the baseline visit and stored at −20 °C prior to analysis. Serum was assayed for osteocalcin, oestradiol, oestrone, oestrone sulphate, testosterone, sex hormone binding globulin, dehydroepiandrosterone sulphate and total alkaline phosphatase. Urine was assayed for calcium, hydroxyproline, oestrone glucuronide and the collagen cross-links pyridinoline and deoxypyridinoline using high-performance liquid chromatography. Bone density was measured at the lumbar spine and femoral neck using dual photon absorptiometry at time 0, 12, 24 and 48 months. The mean annual percentage change in bone density (SE) was −1.41% (0.18) at the lumbar spine and −0.86% (0.22) at the femoral neck. There was no evidence of bimodality or a fast loser subgroup as the rates of change were normally distributed. Both simple and multiple stepwise regression analyses revealed no significant correlation between the rates of change in bone density with any biochemical marker, either individually or in combination, despite the study having sufficient power (80%) to detect a correlation of 0.5 between any biochemical marker levels and bone loss. We conclude that single measurements of these markers of bone turnover and endogenous sex hormones appear unlikely to be clinically useful in predicting early postmenopausal bone loss from either the spine or the hip.
Keywords Biochemical assay Bone densitometry Bone turnover Menopause Osteoporosis References
Hui SL, Slemenda CW, Johnston CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989;111:355–61.
Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK. Appendicular bone density and age predict hip fracture in women. JAMA 1990;263:665–8.
Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72–5.
Johnston CC, Slemenda CW, Peak bone mass, bone loss and risk of fracture. Ostoporosis Int 1994; (Suppl 1):S43–4.
Stepan JJ, Pospichal J, Presi J. Bone loss and biochemical indices of bone remodelling in surgically induced postmenopausal women. Bone 1987;8:279–84.
Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367–73.
Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988;18:191–5.
Christiansen C, Riis BJ, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987;1:1105–8.
Spector TD, Thompson PW, Perry LA, McGarrigle HH, Edwards AC. The relationship between sex steroids and bone mineral content in women soon after the menopause. Clin Endocrinol 1991;34:37–41.
Schlesselman JJ. Planning a longitudinal study. II. Frequency of measurement and study duration. J Chron Dis 1973;26:561–70.
Selby PL, McGarrigle HHG, Peacock M. Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin Endocrinol 1989;30:241–9.
Wathen NC, Perry LA, Rubenstein E, Chard T. A relationship between sex hormone binding globulin and dehydroepiandrosterone sulphate in normally menstruating females. J Gynaecol Endocrinol 1987;1:47–55.
Podenphant J, Larsen NL, Christiansen C. An easy and reliable method for the determination of urinary hydroxyproline. Clin Chim Acta 1984;142:145–8.
James IT, Perrett D, Thompson PW. Rapid assay for hard tissue collagen cross-links using isocratic ion-pair reversed-phase liquid chromatography. J Chromatol 1990;525:43–57.
Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-pair reversed-phase high-performance liquid chromatography. Anal Biochem 1988;169:197–203.
Mole PA, Rae MH, Paterson CR. Urinary oestrogen excretion after the menopause in relation to age and body mass. Ann Nutr Metab 1989;33:246–51.
Christiansen C, Hansen MA, Overgaard K, Riis BJ. Prediction of future fracture risk [abstract]. In: Proceedings of the Fourth International Symposium on Osteoporosis, 1993:52–4.
Pouilles JM, Tremollieres F, Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res 1995;10:1531–6.
Nilas L, Christiansen C. Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 1988;18:529–34.
Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;335:265–9.
Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sayhoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878–83.
Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328:460–4.
Siebel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resporption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993;8:881–9.
Prince R, Dick I, Devine A, et al. Importance of bone resorption in the determination of bone density in women more than 10 years past the menopause. J Bone Miner Res 1993;8:1273–9.
Eastell R, Simmons PS, Colwell A, et al. Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxyypridinoline excretion: effects of growth and ageing. Cli Sci 1992;83:375–82.
Garnero P, Shih Wj, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693–700.
Slemenda C, Hui SL, Longcope C, Johnston CC. Sex steroids and bone mass. J Clin Invest 1998;80:1261–9.
Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: a 12 year study. BMJ 1991;303:961–4.
Walkinshaw MH, Mole PA, Paterson CR. Potential value of urinary oestrogen assays in the identification of fast bone losers after the menopause. Osteoporosis Int 1992;2:205–9.
Davis JW, Grove JS, Ross PD, Vogel JM, Wasnich RD. Relationship between bone mass and rates of bone change at appendicular measurement sites. J Bone Miner Res 1992;7:719–25.
Hui SL, Slemenda CW, Johnston CC. The contribution of bone loss to postmenopausal osteoporosis. Osteoporosis Int 1990;1:30–4.
Google Scholar Copyright information
© European Foundation for Osteoporosis 1996